Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | TACR1 | P25103 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.40 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | RORC | P51449 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30805342 | 0.91 | RORC (0.42) | USP2SMN1; SMN2TACR1HPGDEPHX2 | |
| SCHEMBL26111459 | 0.91 | RORC (0.42) | USP2SMN1; SMN2TACR1HPGDEPHX2 | |
| SCHEMBL5749975 | 0.86 | USP2 (0.46) | USP2SMN1; SMN2TACR1HPGDEPHX2 | |
| SCHEMBL31567039 | 0.86 | USP2 (0.42) | USP2SMN1; SMN2TACR1HPGDEPHX2 | |
| SCHEMBL5750177 | 0.84 | USP2 (0.45) | USP2SMN1; SMN2TACR1HPGDEPHX2 | |
| SCHEMBL31693633 | 0.83 | USP2 (0.46) | USP2SMN1; SMN2HPGDEPHX2TSHR | |
| SCHEMBL21301106 | 0.82 | HPGD (0.40) | USP2SMN1; SMN2TACR1HPGDEPHX2 | |
| SCHEMBL31693650 | 0.81 | USP2 (0.45) | USP2SMN1; SMN2TACR1HPGDEPHX2 | |
| SCHEMBL30693981 | 0.81 | USP2 (0.42) | USP2SMN1; SMN2TACR1HPGDEPHX2 | |
| SCHEMBL1282206 | 0.81 | SMN1; SMN2 (0.42) | USP2SMN1; SMN2TACR1HPGDEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12522593-B2 | Azacycloalkyl carbonyl cyclic amine compound | ALIVEXIS, INC. (JP) | 2026-01-13 | — | — | US | disclosed |
| WO-2025201532-A1 | NOVEL PEGYLATION COMPOUNDS, COMPOSITIONS COMPRISING THE SAME AND USES THEREOF | NUPHASE THERAPEUTICS (SHANGHAI) LIMITED., CO. (CN) | 2025-10-02 | — | — | WO | disclosed |
| EP-4587021-A1 | TREATING PKU WITH CORRECTORS OF MAMMALIAN SLC6A19 FUNCTION | Jnana Therapeutics Inc. (US) | 2025-07-23 | — | — | EP | disclosed |
| CN-120076805-A | Treatment of PKU with a mammalian SLC6A19 functional modifier | 杰那医疗公司 | 2025-05-30 | — | — | CN | disclosed |
| US-20250163041-A1 | AZACYCLOALKYL CARBONYL CYCLIC AMINE COMPOUND | ALIVEXIS, INC. (JP) | 2025-05-22 | — | — | US | disclosed |
| EP-4538264-A1 | AZACYCLOALKYL CARBONYL CYCLIC AMINE COMPOUND | Alivexis, Inc. (JP) | 2025-04-16 | — | — | EP | disclosed |
| CN-119317620-A | Azacycloalkyl carbonyl cyclic amine compounds | 亚力维克希斯股份有限公司 | 2025-01-14 | — | — | CN | disclosed |
| US-20240294520-A1 | AMINO ACID COMPOUNDS WITH UNBRANCHED LINKERS AND METHODS OF USE | PLIANT THERAPEUTICS INC (US) | 2024-09-05 | — | — | US | disclosed |
| CN-113195053-B | Amino acid compounds and methods of use | 普利安特治疗公司 | 2024-08-30 | — | — | CN | disclosed |
| US-20240270742-A1 | SUBSTITUTED AMINO ACIDS AS INTEGRIN INHIBITORS | PLIANT THERAPEUTICS INC (US) | 2024-08-15 | — | — | US | disclosed |
| US-7498326-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2009-03-03 | — | — | US | disclosed |
| US-7312212-B2 | Aminopiperidine derivatives | GLAXO GROUP LIMITED (GB) | 2007-12-25 | — | — | US | disclosed |
| US-7312212-B2 | Aminopiperidine derivatives | GLAXO GROUP LIMITED (GB) | 2007-12-25 | — | — | US | disclosed |
| EP-1419155-B1 | PIPERIDINE DERIVATIVES AS ANTIBACTERIAL AGENTS | SMITHKLINE BEECHAM PLC (GB) | 2006-11-08 | — | — | EP | disclosed |
| US-20050159411-A1 | Aminopiperidine derivatives | GLAXO GROUP LIMITED (GB) | 2005-07-21 | — | — | US | disclosed |
| EP-1470125-A1 | AMINOPIPERIDINE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2004-10-27 | — | — | EP | disclosed |
| US-20040198756-A1 | Medicaments | SMITHKLINE BEECHAM PLC (GB) | 2004-10-07 | — | — | US | disclosed |
| EP-1419155-A2 | PIPERIDINE DERIVATIVES AS ANTIBACTERIAL AGENTS | SMITHKLINE BEECHAM PLC (GB) | 2004-05-19 | — | — | EP | disclosed |
| WO-2003064421-A1 | AMINOPIPERIDINE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2003-08-07 | — | — | WO | disclosed |
| WO-2003010138-A2 | PIPERIDINE DERIVATIVES AS ANTIBACTERIAL AGENTS | SMITHKLINE BEECHAM PLC (GB) | 2003-02-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040198756-A1 | Medicaments | PIGO, PSAP, CD68 | USP2 2709/4885SMN1; SMN2 3564/4885TACR1 1116/4885 |
| US-20240294520-A1 | AMINO ACID COMPOUNDS WITH UNBRANCHED LINKERS AND METHODS OF USE | ITGA2B, ITGB6, ITGB1 | USP2 4286/4885SMN1; SMN2 1460/4885TACR1 2455/4885 |
| US-20250163041-A1 | AZACYCLOALKYL CARBONYL CYCLIC AMINE COMPOUND | NCF1, ELANE, MPO | USP2 4822/4885SMN1; SMN2 1890/4885TACR1 663/4885 |
| US-20240270742-A1 | SUBSTITUTED AMINO ACIDS AS INTEGRIN INHIBITORS | ITGB6, ITGA1, ITGB1 | USP2 4754/4885SMN1; SMN2 2223/4885TACR1 2130/4885 |
| US-20050159411-A1 | Aminopiperidine derivatives | AMPD2, AMPD3, NPEPPS | USP2 4117/4885SMN1; SMN2 2262/4885TACR1 712/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.